A Medical Device Daily
V.I. Technologies (Vitex; Watertown, Massachusetts), a developer of anti-infective products, said it has filed a shelf registration on Form S-3 with the Securities and Exchange Commission (SEC) to offer and sell up to $50 million of equity securities.
The company said it intends to use the proceeds from the sale of any securities to fund its internal discovery and development programs, including the clinical development of its HIV therapeutic drug candidate PA-457, and for other general corporate purposes.
Vitex is developing small-molecule oral drugs for the treatment of HIV and other major human viral diseases. Additionally, its Inactine technology is designed to inactivate a wide range of viruses, bacteria and parasites in blood products, and has demonstrated its ability to remove prion proteins.
The Inactine clinical development program has been suspended while the company continues to address issues relating to immune responses observed in certain patients in Phase III clinical trials (Medical Device Daily, Nov. 29, 2004).
DOBI Medical International (Mahwah, New Jersey) reported that a registration statement on Form SB-2 filed with the SEC on April 25 covering the resale of 36,996,330 shares by certain stockholders has been declared effective by that regulatory body.
Of the 36,996,330 shares registered, 24,000,001 are currently issued and outstanding. DOBI Medical also registered 11,737,500 shares issuable in connection with the exercise of warrants; and 1,258,829 shares issuable in connection with the conversion of its Series A convertible preferred stock.
Of the 24,000,001 shares issued and outstanding, about 400,000 are held by the company’s directors and executive officers. The company said it would not receive any of the proceeds from any shareholders who may sell their shares, except by those who may exercise warrants.
DOBI Medical is a medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal vascularization associated with tumors.
In other financing activity:
• Impac Medical Systems (Mountain View, California), part of the Elekta Group (Stockholm, Sweden) and a provider of information technology solutions for oncology care, and the Mattson Jack Group (MJG; St. Louis), a provider of healthcare consulting services, have expanded a licensing agreement that will grant MJG access to Impac’s oncology-specific electronic medical record (EMR) for point-of-care data, in addition to data from its National Oncology DataBase (NODB), to be used in MJG’s Patient Metrics module of Cancer!MPact.
Like the NODB, the EMR data is provided from participating Impac customers. According to the companies, the new de-identified EMR-derived dataset has the potential for adding a unique and expanded body of information from hundreds of thousands of cancer cases in near real time. When added to data from the more than 2 million NODB cancer registry-derived cases, it greatly augments the breadth and depth of the resultant information.
• LifePoint Hospitals (Brentwood, Tennessee) reported that its wholly owned subsidiary, Historic LifePoint Hospitals, formerly known as LifePoint Hospitals, has called for redemption of all the $221,000,000 outstanding principal amount of its 4-1/2% convertible subordinated notes due 2009, at a redemption price of 102.571% of the principal amount, plus accrued and unpaid interest to, but excluding, the redemption date, which is June 15. Notice of redemption of the notes was being mailed to all holders of record on Monday.
Historic LifePoint intends to settle all redemptions in cash from cash on hand, borrowing under the existing revolving credit facility or new financing. Holders may convert their notes into common stock of LifePoint Hospitals at any time on or prior to the close of business on the business day immediately preceding the redemption date at a conversion rate of 21.1153 shares of LifePoint Hospitals common stock per $1,000 principal amount of notes, or an effective conversion price of about $47.36 per share of LifePoint Hospitals common stock.
U.S. Bank National Association is the trustee under the indenture governing the notes and is the paying agent in connection with the redemption.
LifePoint Hospitals is focused on providing healthcare services in non-urban communities.